OncLive
LightNews LightNews
banner
onclive.bsky.social
OncLive
@onclive.bsky.social
960 followers 140 following 2.8K posts
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Posts Replies Media Videos
onclive.bsky.social
WATCH: Martha Welman, MD, discusses findings from a study of strategic screening initiatives aimed at reducing breast cancer diagnostic disparities. #bcsm #oncology
www.onclive.com/view/dr-welm...
Dr Welman on the Effects of Patient Navigation on Breast Cancer Screening and Diagnosis | OncLive
Martha Welman, MD, discusses findings from a study of strategic screening initiatives aimed at reducing breast cancer diagnostic disparities.
www.onclive.com
February 17, 2026 at 9:15 PM
onclive.bsky.social
Encorafenib/Cetuximab Plus FOLFIRI Prolongs PFS Over SOC in BRAF V600E–Mutant mCRC
#crcsm #oncology
www.onclive.com/view/encoraf...
Encorafenib/Cetuximab Plus FOLFIRI Prolongs PFS Over SOC in BRAF V600E–Mutant mCRC | OncLive
Topline data from cohort 3 of BREAKWATER showed improvements in key secondary end points of PFS and OS in previously treated, BRAF V600E–mutant mCRC.
hubs.li
February 17, 2026 at 5:23 PM
onclive.bsky.social
📷Vikram C. Gorantla, MD, of @upmchillmancc.bsky.social, discusses the importance of patient selection for breast cancer treatment optimization. #bcsm #oncology

Watch additional video insights from Dr Gorantla on our site: www.onclive.com/view/dr-gora...
February 16, 2026 at 7:04 PM
onclive.bsky.social
Adjuvant Selpercatinib Improves EFS in Early-Stage RET Fusion–Positive NSCLC #medtwitter #oncology #lcsm #nsclc
www.onclive.com/view/adjuvan...
Adjuvant Selpercatinib Improves EFS in Early-Stage RET Fusion–Positive NSCLC | OncLive
Improved EFS was seen when selpercatinib was administered as adjuvant therapy vs placebo in early-stage RET fusion–positive NSCLC.
www.onclive.com
February 16, 2026 at 4:40 PM
onclive.bsky.social
WATCH: Martha Welman, MD, discusses patient navigation interventions aiming to address unmet needs in the breast cancer screening and diagnosis pathway. #bcsm #oncology
www.onclive.com/view/dr-welm...
Dr Welman on a Study of the Effects of Patient Navigation on Breast Cancer Screening | OncLive
Martha Welman, MD, discusses patient navigation interventions aiming to address unmet needs in the breast cancer screening and diagnosis pathway.
www.onclive.com
February 16, 2026 at 3:07 PM
onclive.bsky.social
Orca-T Plus Allogeneic CAR T-Cell Therapy Signals Paradigm Shift in B-ALL @stanfordmedicine.bsky.social @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #leusm #hematology
www.onclive.com/view/orca-t-...
Orca-T Plus Allogeneic CAR T-Cell Therapy Signals Paradigm Shift in B-ALL | OncLive
Alfonso Molina, MD, MPH, discusses a phase 1 trial evaluating Orca-T with allogeneic CAR T-cell therapy in high-risk B-cell acute lymphoblastic leukemia.
www.onclive.com
February 16, 2026 at 1:32 PM
onclive.bsky.social
Martha Welman, MD, discusses findings from a study of resources used to reduce time to breast cancer screening and diagnosis. #bcsm

Stay tuned for more from the interview, only on our site! In the meantime, catch up on our coverage of #SABCS25: www.onclive.com/conference/s...
February 13, 2026 at 9:42 PM
onclive.bsky.social
Third-Line Treatment Strategy in mCRC Shifts Focus From Tumor Response to Disease Stabilization #oncology #CRC #colorectalcancer
www.onclive.com/view/third-l...
Third-Line Treatment Strategy in mCRC Shifts Focus From Tumor Response to Disease Stabilization | OncLive
Benjamin A. Weinberg, MD, FACP, discusses the specific therapeutic goals and challenges of third-line metastatic colorectal cancer management.
www.onclive.com
February 13, 2026 at 8:58 PM
onclive.bsky.social
WATCH: Vikram C. Gorantla, MD, discusses real-world treatment patterns with T-DXd vs tucatinib-based therapy in HER2-positive breast cancer with brain metastases.
@upmchillmancc.bsky.social #bcsm #oncology
www.onclive.com/view/dr-gora...
Dr Gorantla on Treatment Patterns With HER2-Directed Therapy Across Breast Cancer Subsets | OncLive
Vikram C. Gorantla, MD, discusses real-world treatment patterns with T-DXd vs tucatinib-based therapy in HER2-positive breast cancer with brain metastases.
www.onclive.com
February 13, 2026 at 8:30 PM
onclive.bsky.social
WATCH: Vikram C. Gorantla, MD, discusses future directions for sequencing available therapies for patients with breast cancer who develop brain metastases. @upmchillmancc.bsky.social #bcsm #oncology
www.onclive.com/view/dr-gora...
Dr Gorantla on HER2-Directed Treatment Sequencing in Breast Cancer Brain Metastases | OncLive
Vikram C. Gorantla, MD, discusses future directions for sequencing available therapies for patients with breast cancer who develop brain metastases.
www.onclive.com
February 13, 2026 at 8:29 PM
onclive.bsky.social
Non-Chemo, Biomarker-Driven Perioperative Strategies Highlight Bladder Cancer Presentations to Watch at ASCO GU 2026

Discover the bladder cancer topics and data experts are most anticipating at @theaacr.bsky.social #GU26 www.onclive.com/view/non-che...
Non-Chemo, Biomarker-Driven Perioperative Strategies Highlight Bladder Cancer Presentations to Watch at ASCO GU 2026 | OncLive
Bladder cancer experts share the most anticipated abstracts expected at the 2026 Genitourinary Cancers Symposium.
www.onclive.com
February 13, 2026 at 2:38 PM
onclive.bsky.social
4-Year Data Underscore Durable Efficacy With Avapritinib in Advanced Systemic Mastocytosis @ASH_hematology #oncology www.onclive.com/view/4-year-...
4-Year Data Underscore Durable Efficacy With Avapritinib in Advanced Systemic Mastocytosis | OncLive
Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, discusses 4-year data from the PATHFINDER trial of avapritinib in advanced systemic mastocytosis.
www.onclive.com
February 12, 2026 at 10:49 PM
onclive.bsky.social
FDA Approves Optune Pax for Locally Advanced #PancreaticCancer 🧬💡

Read the full article here ⬇️ www.onclive.com/view/fda-app...
FDA Approves Optune Pax for Locally Advanced Pancreatic Cancer | OncLive
The portable, non-invasive device has been approved for concomitant use with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.
www.onclive.com
February 12, 2026 at 3:38 PM
onclive.bsky.social
👀 What presentations were most noteworthy from the #Tandem2026? Sign up to read insights from #hematology experts about research expected to propel cell therapy developments! @osucccjames.bsky.social @ohsunews.bsky.social @stanfordmedicine.bsky.social #Oncology
www.onclive.com/view/experts...
February 12, 2026 at 3:07 PM
onclive.bsky.social
Long-Term Ibrutinib Plus Venetoclax Data Demonstrate Durable, Strong Responses in R/R MCL #lymsm #hematology #oncology
www.onclive.com/view/long-te...
Long-Term Ibrutinib Plus Venetoclax Data Demonstrate Durable, Strong Responses in R/R MCL | OncLive
Ibrutinib plus venetoclax yielded sustained complete response rates and a favorable safety profile in relapsed/refractory mantle cell lymphoma.
www.onclive.com
February 11, 2026 at 10:52 PM
onclive.bsky.social
PD-1 Inhibition Plus Chemotherapy Offers Survival Benefits in Frontline HNSCC #oncology #HNSCC
www.onclive.com/view/pd-1-in...
PD-1 Inhibition Plus Chemotherapy Offers Survival Benefits in Frontline HNSCC | OncLive
Real-world data showed that adding PD-1 inhibitors to induction chemotherapy extended OS and PFS vs chemotherapy alone in frontline HNSCC.
www.onclive.com
February 11, 2026 at 10:32 PM
onclive.bsky.social
PD-L1 IHC 22C3 pharmDx Nets Companion Diagnostic Approval for Pembrolizumab in Ovarian Cancer
#ovca #oncology
www.onclive.com/view/pd-l1-i...
PD-L1 IHC 22C3 pharmDx Nets Companion Diagnostic Approval for Pembrolizumab in Ovarian Cancer | OncLive
The FDA approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic for patients with PD-L1–positive ovarian cancer who could receive pembrolizumab.
www.onclive.com
February 11, 2026 at 6:38 PM
onclive.bsky.social
Myeloablative Orca-Q Yields High Engraftment Rates in High-Risk Hematologic Malignancies With Haploidentical Donors @astct.bsky.social @cibmtr.bsky.social #Tandem2026 #Oncology

www.onclive.com/view/myeloab...
Myeloablative Orca-Q Yields High Engraftment Rates in High-Risk Hematologic Malignancies With Haploidentical Donors | OncLive
Orca-Q produced to high engraftment rates and promising survival outcomes in high-risk hematologic malignancies with haploidentical donors.
www.onclive.com
February 11, 2026 at 6:36 PM
onclive.bsky.social
FDA Accepts sNDA Filing of Aminolevulinic Acid Topical Gel for Superficial Basal Cell Carcinoma #oncology #BCC #melanoma #skincancer www.onclive.com/view/fda-acc...
FDA Accepts sNDA Filing of Aminolevulinic Acid Topical Gel for Superficial Basal Cell Carcinoma | OncLive
An sNDA has been filed with the FDA for aminolevulinic acid topical gel plus RhodoLED red light lamps in superficial basal cell carcinoma.
www.onclive.com
February 11, 2026 at 4:32 PM
onclive.bsky.social
WATCH: Vikram C. Gorantla, MD, discusses an analysis of T-DXd vs tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer with brain metastases. @upmchillmancc.bsky.social #bcsm #oncology
www.onclive.com/view/dr-gora...
Dr Gorantla on a Real-World Study of HER2-Directed Breast Cancer Therapy | OncLive
Vikram C. Gorantla, MD, discusses an analysis of T-DXd vs tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer with brain metastases.
www.onclive.com
February 10, 2026 at 11:07 PM
onclive.bsky.social
Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC @emoryuniversity.bsky.social @winshipcancer.emory.edu #pcsm #oncology
www.onclive.com/view/real-wo...
Real-World Analysis Establishes OS Advantage With Apalutamide Plus ADT vs Darolutamide in mCSPC | OncLive
Mehmet Bilen, MD, discusses a retrospective analysis of patients receiving apalutamide vs darolutamide for metastatic castration-sensitive prostate cancer.
www.onclive.com
February 10, 2026 at 10:56 PM
onclive.bsky.social
BREAKING 🚨: @fda.gov Approves Pembrolizumab Plus Paclitaxel +/- Bevacizumab for PD-L1+ PROC #ovca #gynsm #FDAapproved

Read more 📰: www.onclive.com/view/fda-app...
FDA Approves Pembrolizumab Plus Paclitaxel With/Without Bevacizumab for PD-L1+ Platinum-Resistant Ovarian Cancer | OncLive
The FDA approved pembrolizumab with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian cancer, with a companion diagnostic.
www.onclive.com
February 10, 2026 at 9:16 PM
onclive.bsky.social
Zanidatamab Triplet May Be a “Game Changer” for the Frontline Management of HER2+ GEA @orlandohealth.bsky.social @weillcornell.bsky.social #oncology #GEA #GIcancer www.onclive.com/view/zanidat...
Zanidatamab Triplet May Be a “Game Changer” for the Frontline Management of HER2+ GEA | OncLive
Manish A. Shah, MD, and Raji Shameem, MD, discuss potentially paradigm-shifting results from the HERIZON-GEA-01 study.
www.onclive.com
February 10, 2026 at 8:25 PM
onclive.bsky.social
Following the FDA's draft guidance on MRD end points to support accelerated approvals in multiple myeloma, OncLive spoke with experts to gather their insights what this guidance means for future clinical trials #mmsm #oncology

Sign up and read more: www.onclive.com/view/fda-gui...
FDA Guidance Signals Shift Toward MRD-Driven Accelerated Approvals in Multiple Myeloma | OncLive
Experts break down the FDA’s draft guidance on the use of MRD end points to support accelerated drug approvals in multiple myeloma.
www.onclive.com
February 10, 2026 at 8:18 PM
onclive.bsky.social
Multidisciplinary, Patient-Specific Factors Guide Treatment Decisions in Cutaneous Squamous Cell Carcinoma @nufeinbergmss.bsky.social #oncology www.onclive.com/view/multidi...
Multidisciplinary, Patient-Specific Factors Guide Treatment Decisions in Cutaneous Squamous Cell Carcinoma | OncLive
Sunandana Chandra, MD, MS, discusses how resectability, anatomy, prior therapy, and patient fitness guide multidisciplinary treatment decisions in CSCC.
www.onclive.com
February 10, 2026 at 2:20 PM